行情

NCNA

NCNA

NuCana
NASDAQ

实时行情|Nasdaq Last Sale

8.00
+0.30
+3.90%
休市 16:00 09/20 EDT
开盘
7.84
昨收
7.70
最高
8.00
最低
7.60
成交量
1.80万
成交额
--
52周最高
25.82
52周最低
4.010
市值
2.54亿
市盈率(TTM)
-12.7898
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NCNA 新闻

  • 特朗普呼吁将利率降至零以下:我们应比别人少付利息
  • 新浪美股.38分钟前
  • 网易“潜伏”海外:攻占日韩 “出师”印度 远征非洲
  • 新浪美股.43分钟前
  • 股价迄今飙升超300% Roku投资者为何急跳墙?
  • 新浪财经-自媒体综合.1小时前
  • 美欧飞机补贴案恐再掀巨浪 WTO最早9月30日宣判
  • 新浪美股.2小时前

更多

所属板块

生物技术和医学研究
+0.62%
制药与医学研究
+0.95%

热门股票

名称
价格
涨跌幅

NCNA 简况

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline of products includes Acelarin, NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. The Company is evaluating Acelarin in four clinical trials across several solid tumor indications. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil for the treatment of a wide range of cancers. NUC-3373 is in a Phase I trial for the potential treatment of a wide range of solid tumor cancers. NUC-7738 is a ProTide transformation of cordycepin, a novel nucleoside analog.
展开

Webull提供NuCana PLC (ADR)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。